Fig. 4: Model simulations overlaid with the TGI measured for various regimens in experimental study 3 in HBCx-9 tumour model. | British Journal of Cancer

Fig. 4: Model simulations overlaid with the TGI measured for various regimens in experimental study 3 in HBCx-9 tumour model.

From: Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs

Fig. 4

Treatment starts at Day 1, last dosing at Day 28 (dotted line). Solid line: simulation. Markers and error bars: data, mean tumour volume ± SEM. Data for each arm are shown when at least 6 out of 8 mice are still in the experiment. The arms are split across panels for clarity: vehicle and monotherapy (a), and combination (b-d). In all PARPi treated arms talazoparib is given twice a day at 0.15 mg/kg. Unless specified in the legend, gartisertib is given once a day (qd, b) x28 days, twice a week (2 qwk, c) or once a week (1 qwk, d) x4 weeks, at the specified dose.

Back to article page